Hormone Health Data and Research Act

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 9077 Introduced in House (IH)]

<DOC>

119th CONGRESS
  2d Session
                                H. R. 9077

  To direct the Director of the National Institutes of Health and the 
Secretary of Health and Human Services to evaluate hormone variability 
      and hormone testing, respectively, in women with respect to 
                             perimenopause.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                              May 29, 2026

 Ms. Scholten introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
  To direct the Director of the National Institutes of Health and the 
Secretary of Health and Human Services to evaluate hormone variability 
      and hormone testing, respectively, in women with respect to 
                             perimenopause.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Hormone Health Data and Research 
Act''.

SEC. 2. STUDIES ON HORMONE VARIABILITY AND HORMONE TESTING WITH RESPECT 
              TO PERIMENOPAUSE.

    (a) NIH Study.--The Director of the National Institutes of Health 
shall evaluate any evidence published on or prior to the date of 
enactment of this Act that relates to--
            (1) the variability of hormone levels in a woman before 
        such woman experiences symptoms of perimenopause; and
            (2) any baseline pattern in such variability.
    (b) U.S. Preventive Services Task Force Study.--The Secretary of 
Health and Human Services, acting through the United States Preventive 
Services Task Force, shall review any evidence published on or prior to 
the date of enactment of this Act related to the clinical utility of 
hormone testing, including whether baseline information obtained on the 
hormone levels of a woman before such woman experiences symptoms of 
perimenopause meaningfully informs the diagnosis or management of 
perimenopause for such woman.
    (c) Report.--Not later than 18 months after enactment of this Act, 
NIH and USPSTF shall submit a report to the Committees on 
Appropriations of the House of Representatives and Senate, the 
Committee on Energy and Commerce of the House of Representatives, and 
the Committee on Health, Education, Labor, and Pensions of the Senate 
summarizing findings, identifying evidence gaps, and providing 
recommendations for future research or clinical guidance.
                                 <all>